Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of the immune enhancement effect of CpG ODN on periodontitis genetic vaccine by RNA sequencing

ABSTRACT: Periodontitis is one of the main causes of tooth loss in adults. Early diagnosis and intervention can effectively control the progression of periodontitis. The research group constructed a periodontitis genetic vaccine in the early stage and improved the immunogenicity of the body by adding CpG oligonucleotide (CpG ODN). The purpose of this study was to analyse the potential mechanism by which CpG ODN adjuvants enhance the preventive effect of periodontitis genetic vaccines at the molecular level by transcriptome sequencing and to screen out key genes and signaling pathways for follow-up research.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE206597 | GEO | 2025/06/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from murine vaginal samples following adjuvant treatment

Project description:Vaccine research today is focused on using safer, highly purified or recombinant antigens with poor immunogenicity, which has created a need for potent adjuvants. Rational design of effective and safe mucosal adjuvants for human use necessitates a thorough understanding of the mode of action of successful candidate adjuvants. We used microarray to comprehend the molecular signatures of mucosal adjuvants in the mouse vagina. The adjuvants studied, CpG-ODN and ‚âà√≠¬¨¬±-GalCer have previously been shown to be potent mucosal adjuvants in mice when administrered together with a glycoprotein from HSV-2. Two individual experiments were performed, called ES1 and ES2, each experiment contained 4 groups of mice. All mice were pre-treated with progesteron (DP) before intravaginally recieveing either CpG ODN, alpha-GalCer or their respective buffers, PBS and PBS/Tween. Vaginas were excised at 3 different time-points; 4h, 24h and 48h following adjuvant delivery.

2011-12-30 | E-GEOD-27149 | biostudies-arrayexpress

Identification of the immune enhancement effect of CpG ODN on periodontitis genetic vaccine by RNA sequencing

Project description:Identification of the immune enhancement effect of CpG ODN on periodontitis genetic vaccine by RNA sequencing

| PRJNA851444 | ENA

Expression data from murine vaginal samples following adjuvant treatment

2011-12-30 | GSE27149 | GEO

Gene expression profile of IGROV1 cells after in vitro treatment with CpG-ODN

2011-04-01 | GSE23442 | GEO

Transcription profiling of Bos taurus CD14+ purified bovine monoctye stimulation with CpG ODN 2007 vs. GpC ODN 2007, CpG 2007 vs. Control, GpC 2007 vs. Control and Media vs Control (

Project description:CD14+ purified bovine monoctye stimulation with CpG ODN 2007 vs. GpC ODN 2007, CpG 2007 vs. Control, GpC 2007 vs. Control and Media vs Control (Control is unstimluated CD14+ purified bovine monocytes at time zero). Before stimulation, the CD14+ purified bovine monocytes were rested for 20 h. Then the cells were stimulated for 4hrs.

2005-01-01 | E-FPMI-2 | biostudies-arrayexpress

An integrated transcriptomics and metabolomics study of the immune response of newly hatched chicks to the CpG-ODN stimulation

Project description:This study aims at identifying a dual transcriptomics and metabolomics blood signature following administration of CpG-ODN (cytosine-phosphate-guanine oligodeoxynucleotides), a reference immune-stimulatory molecule. A clinical study was conducted with chicks and transcriptomics and metabolomics analyses were performed on whole-blood and plasma samples respectively. Statistical analyses resulting in lists of differentially expressed genes and metabolites with different abundance were identified in chicks treated with CpG-ODN. The results showed that CpG-ODN activates the innate immune systems within hours following administration and its effect lasts over time, as metabolomic and transcriptomic profiles are still varying at 6 days after administration.

2019-10-17 | GSE138956 | GEO

Gene expression profile of IGROV1 cells after treatment of saline or CpG-ODN

Project description:This SuperSeries is composed of the following subset Series: GSE23440: Gene expression profiling of IGROV1 cells after in vitro treatment with ascitic fluid from human ovarian cancer bearing mice GSE23441: IGROV1 gene expression analysis after in vivo locoregional treatment with CpG-ODN GSE23442: Gene expression profile of IGROV1 cells after in vitro treatment with CpG-ODN Refer to individual Series

2011-04-01 | E-GEOD-23491 | biostudies-arrayexpress

Gene expression profile of IGROV1 cells after in vitro treatment with CpG-ODN

Project description:CpG-ODN is a potent immuno-stimulatory molecule. In order to exclude a direct effect of murine CpG-ODN on IGROV1 human ovarian cancer cell line a gene expression experiment was performed. The ovarian cancer cell line IGROV-1 was obtained from the ATCC (Rockville, MD). Cells were routinely maintained in RPMI medium 1640 (Sigma, St. Louis, MO) supplemented with 10% FCS (Sigma) and 2 mM glutamine (Cambrex, East Rutherford, NJ). Cells were maintained at 37°C in a water-saturated atmosphere of 5% CO2 in air. 1x106 IGROV-1 cells were seeded in 6-well plates and, after seeding, cells were treated with 10uM of CpG-ODN in culture medium [phosphorothioated ODN1826 (5’-TCCATGACGTTCCTGACGTT-3’), TriLink Biotechnologies (San Diego, CA, USA)] for 24 hours. At the end of treatment, cells were collected and RNA extracted.

2011-04-01 | E-GEOD-23442 | biostudies-arrayexpress

Characterization of three CpG ODN classes in B cells

Project description:Characterization of three CpG ODN classes in B cells

| PRJNA597990 | ENA

IGROV1 miRNA expression analysis after in vivo locoregional treatment with CpG-ODN

Project description:We reported that peri-tumoral CpG-ODN treatment, probably activating TLR9-expressing cells present in the tumor microenvironment, sensitized cancer cells to DNA-damaging chemotherapy (Cancer Res 2011 Oct 15;71(20):6382-90). Here, we investigated whether this treatment induces a modulation of miRNAs and their involvement in chemotherapy sensitivity. Twenty miRNAs were found differentially expressed in tumors from CpG-ODN-treated mice versus controls. Evaluation of the role of miR-424, miR-340 and miR-302b on cisplatin sensitivity revealed that ectopic expression of miR-302b (up-modulated in our array) in IGROV1 cells significantly improved cisplatin activity. The identification of miRNAs able to modify sensitivity to chemotherapy treatment will provide an experimental base for its future possible use as a target or tool of specific therapies.

2013-03-31 | GSE41783 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data